Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Sets up US subsidiary

YORK, UK -- (Marketwire) -- 11/26/12 --






          Tissue Regenix sets up United States subsidiary
           to target growing regenerative medicine market

Tissue Regenix appoints Greg Bila President, Tissue Regenix USA

YORK, 26 November 2012. Tissue Regenix Group plc ('Tissue Regenix') has
set up a subsidiary company in the United States, as part of its
commercialisation strategy for its dCELL® technology platform.

Tissue Regenix is also pleased to announce the recruitment of Greg Bila
from Kinetic Concepts Inc. ('KCI') as President of Tissue Regenix USA.
Greg's recent career at KCI has spanned a number of sales & marketing
roles and brings over 20 years' experience in pharmaceutical and
medical device fields.

Tissue Regenix will use its patented dCELL® technology to target a
number of areas. Work will focus initially on applying the dCELL® to
the treat a number of chronic diseases but, over time, could be
developed for other applications including vascular repair, heart valve
replacement and knee repair. Tissue Regenix's dCELL® technology have
delivered encouraging interim data.

Antony Odell, Managing Director of Tissue Regenix commented: "This is a
significant step in the development of Tissue Regenix. It is an
excellent signal of the strength of TR's proposition that we can
attract people of Greg's calibre and experience, we look forward to
advancing our plans in the US with him at the helm. The United States
presents an opportunity to establish our platform dCELL® technology in
a market potentially worth hundreds of millions of dollars."

Greg Bila, President of Tissue Regenix Wound Care Inc. said: "I am
excited to be able to join Tissue Regenix at the beginning of its
expansion into the United States. TR's dCELL® technology will be a
welcome offering for the treatment of number of diseases and the
potential indications are attractive."

The potential advantages of the Company's dCELL technology over other
types of decellularised tissue scaffolds was underpinned at Tissue
Regenix technology day in October by Dr Alan Dardik, Associate
Professor of Surgery at Yale University, who has conducted pre-clinical
studies of Tissue Regenix dCELL® vascular patch and published the
results in the scientific journal PLoS ONE.

Speaking about those studies Dr Dardik commented: "I have to say my
impression is it's the closest thing on the market to a tissue
engineered patch. It's the next technology. Other companies are trying
to attract stem-cells but they've already got the stem cells that are
coming into their patch."



ENDS


For Further Information

Tissue Regenix Group plc:         01904 435 176
Antony Odell

Newgate Communications:
Alistair Kellie                   07801 234598
Andrew Adie                       07970 256512
Martin Greig                      07584 221513





About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of
regenerative medicine. The company's patented decellularisation
('dCELL®) technology removes DNA and other cellular material from
animal and human tissue leaving an acellular tissue scaffold which is
not rejected by the patient's body which can then be used to repair
diseased or worn out body parts. The potential applications of this
process are diverse and address many critical clinical needs such as
vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.



                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contacts:
RNS
Customer
Services
0044-207797-4400
Email Contact
http://www.rns.com

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
Just last year, a CA Technologies and Vanson Bourne survey revealed that DevOps was not a sure-fire hit— 16 percent of senior IT professionals did not know what DevOps was, and an additional 18 percent had no plans to adopt it. Fast forward one year and the results tell an entirely new...
Last week I told you about my family’s experience with an under the skin glucose sensor that tracks blood sugar levels. While this Internet of Things trend often takes the form of a thermostat, light bulb or coffee machine, the medical field has been using sensors for a while and it is...
In my hunt for the mysterious DevOps practice, I’ve been let down. DevOps are hard to find. When you find them, they do not exactly do what you think they should do. Some DevOps teams only execute on automation for dev; while others are operations folks with a new name; and still other...
Don’t emphasize network security at the cost of endpoint security; the two can be integrated and work hand in hand. The result is a safer, more secure business ready for the challenges of the future.
Most forward-looking CEOs have already made their move to prepare for the future that they foresee – where business technology is a key deciding factor for them to attain ongoing commercial prosperity. This new digital-propelled environment will profoundly change business processes, al...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE